NeuroEM Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- (In Progress)
- Latest Deal Amount
-
$2M
- Investors
-
4
NeuroEM Therapeutics General Information
Description
Developer of brain health medical devices designed to address cognitive impairment associated with neurodegenerative conditions. The company offers transcranial electromagnetic treatment using radio frequencies to target brain regions associated with Alzheimer's disease and beta-amyloid and p-tau proteins, enabling healthcare professionals to evaluate and treat cognitive impairment associated with neurodegenerative diseases.
Contact Information
Website
www.neuroem.comCorporate Office
- 501 East Kennedy Boulevard
- Suite 650
- Tampa, FL 33602
- United States
Corporate Office
- 501 East Kennedy Boulevard
- Suite 650
- Tampa, FL 33602
- United States
NeuroEM Therapeutics Timeline
NeuroEM Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series A) | 01-Jun-2026 | $2M | In Progress | Generating Revenue/Not Profitable | ||
| 9. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue/Not Profitable | |||
| 8. Later Stage VC (Series A) | 29-Aug-2025 | Completed | Generating Revenue/Not Profitable | |||
| 7. Later Stage VC (Series B) | Cancelled | Generating Revenue/Not Profitable | ||||
| 6. Grant | 01-Apr-2021 | Completed | Generating Revenue/Not Profitable | |||
| 5. Grant | 01-Jan-2017 | Completed | Generating Revenue/Not Profitable | |||
| 4. Early Stage VC | 02-May-2016 | Completed | Startup | |||
| 3. Angel (individual) | Completed | Startup | ||||
| 2. Grant | 01-Jan-2016 | $515K | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
NeuroEM Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 325,458 | $0.001000 | 3% | $1.35 | $1.35 | 1x | $1.35 | 2.97% |
| Series A-1 | 303,612 | $0.001000 | 3% | $1.27 | $1.27 | 1x | $1.27 | 2.77% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NeuroEM Therapeutics Comparisons
Industry
Financing
Details
NeuroEM Therapeutics Competitors (1)
One of NeuroEM Therapeutics’s competitors is Cognito Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cognito Therapeutics | Venture Capital-Backed | Cambridge, MA |
NeuroEM Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeuroEM Therapeutics Patents
NeuroEM Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023101661-A1 | Treatment of brain cancers by transcranial electromagnetic treatment | Inactive | 30-Nov-2021 | ||
| EP-4419195-A1 | Brain immunoregulation through transcranial electromagnetic treatment | Pending | 22-Oct-2021 | ||
| EP-4419195-A4 | Brain immunoregulation through transcranial electromagnetic treatment | Pending | 22-Oct-2021 | ||
| WO-2023069117-A1 | Brain immunoregulation through transcranial electromagnetic treatment | Inactive | 22-Oct-2021 | ||
| EP-4142869-A1 | Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment | Active | 01-May-2020 | A61N1/40 |
NeuroEM Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeuroEM Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BlueLake Ventures | Venture Capital | Minority | ||
| Lunch Pail Ventures | Angel Group | Minority | ||
| Opus8 | PE/Buyout | Minority | ||
| National Institutes of Health | Government |
NeuroEM Therapeutics FAQs
-
When was NeuroEM Therapeutics founded?
NeuroEM Therapeutics was founded in 2013.
-
Where is NeuroEM Therapeutics headquartered?
NeuroEM Therapeutics is headquartered in Tampa, FL.
-
What is the size of NeuroEM Therapeutics?
NeuroEM Therapeutics has 7 total employees.
-
What industry is NeuroEM Therapeutics in?
NeuroEM Therapeutics’s primary industry is Therapeutic Devices.
-
Is NeuroEM Therapeutics a private or public company?
NeuroEM Therapeutics is a Private company.
-
What is the current valuation of NeuroEM Therapeutics?
The current valuation of NeuroEM Therapeutics is .
-
What is NeuroEM Therapeutics’s current revenue?
The current revenue for NeuroEM Therapeutics is .
-
How much funding has NeuroEM Therapeutics raised over time?
NeuroEM Therapeutics has raised $6.18M.
-
Who are NeuroEM Therapeutics’s investors?
BlueLake Ventures, Lunch Pail Ventures, Opus8, and National Institutes of Health have invested in NeuroEM Therapeutics.
-
Who are NeuroEM Therapeutics’s competitors?
Cognito Therapeutics is a competitor of NeuroEM Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
